-
A randomized, double-blind, controlled study to evaluate clinical efficacy and safety of novel filmogen osmotic treatment for pharyngitis
Monika Rousse, Hendrik Schutte, Martine Guy, Gael Clairefond, Ravi Shrivastava
Research Article: Clinical Investigation
-
A randomized, double-blind, controlled study to evaluate clinical efficacy and safety of novel filmogen osmotic treatment for pharyngitis
Monika Rousse, Hendrik Schutte, Martine Guy, Gael Clairefond, Ravi Shrivastava
Research Article: Clinical Investigation
-
A randomized, double-blind, controlled study to evaluate clinical efficacy and safety of novel filmogen osmotic treatment for pharyngitis
Monika Rousse, Hendrik Schutte, Martine Guy, Gael Clairefond, Ravi Shrivastava
Research Article: Clinical Investigation
-
A randomized, double-blind, controlled study to evaluate clinical efficacy and safety of novel filmogen osmotic treatment for pharyngitis
Monika Rousse, Hendrik Schutte, Martine Guy, Gael Clairefond, Ravi Shrivastava
Research Article: Clinical Investigation
-
A randomized, double-blind, controlled study to evaluate clinical efficacy and safety of novel filmogen osmotic treatment for pharyngitis
Monika Rousse, Hendrik Schutte, Martine Guy, Gael Clairefond, Ravi Shrivastava
Research Article: Clinical Investigation
-
A randomized, double-blind, controlled study to evaluate clinical efficacy and safety of novel filmogen osmotic treatment for pharyngitis
Monika Rousse, Hendrik Schutte, Martine Guy, Gael Clairefond, Ravi Shrivastava
Research Article: Clinical Investigation
-
Managing safety in early phase trials: is there a gold standard?
Anja Slikkerveer
Editorial: Clinical Investigation
-
Managing safety in early phase trials: is there a gold standard?
Anja Slikkerveer
Editorial: Clinical Investigation
-
Managing safety in early phase trials: is there a gold standard?
Anja Slikkerveer
Editorial: Clinical Investigation
-
Managing safety in early phase trials: is there a gold standard?
Anja Slikkerveer
Editorial: Clinical Investigation
-
Managing safety in early phase trials: is there a gold standard?
Anja Slikkerveer
Editorial: Clinical Investigation
-
Managing safety in early phase trials: is there a gold standard?
Anja Slikkerveer
Editorial: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Clinical Trail Prospective: Clinical Investigation
-
Considerations on clinical trials of leprosy treatment: need of novel drug combinations
Ximena Illarramendi, Maria Leide Wand del Rey de Oliveira, Anna Maria Sales, Jose Augusto da Costa Nery, Euzenir Nunes Sarno
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations on clinical trials of leprosy treatment: need of novel drug combinations
Ximena Illarramendi, Maria Leide Wand del Rey de Oliveira, Anna Maria Sales, Jose Augusto da Costa Nery, Euzenir Nunes Sarno
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations on clinical trials of leprosy treatment: need of novel drug combinations
Ximena Illarramendi, Maria Leide Wand del Rey de Oliveira, Anna Maria Sales, Jose Augusto da Costa Nery, Euzenir Nunes Sarno
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations on clinical trials of leprosy treatment: need of novel drug combinations
Ximena Illarramendi, Maria Leide Wand del Rey de Oliveira, Anna Maria Sales, Jose Augusto da Costa Nery, Euzenir Nunes Sarno
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations on clinical trials of leprosy treatment: need of novel drug combinations
Ximena Illarramendi, Maria Leide Wand del Rey de Oliveira, Anna Maria Sales, Jose Augusto da Costa Nery, Euzenir Nunes Sarno
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations on clinical trials of leprosy treatment: need of novel drug combinations
Ximena Illarramendi, Maria Leide Wand del Rey de Oliveira, Anna Maria Sales, Jose Augusto da Costa Nery, Euzenir Nunes Sarno
Review: Clinical Trail Outcomes: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Does enrollment in a trial carry a survival advantage for patients?
Tal Shahar, Uri Rozovski, Zvi Ram
Editorial: Clinical Investigation
-
Investigating the investigators: research malfeasance
Blair Henry
Editorial: Clinical Investigation
-
Investigating the investigators: research malfeasance
Blair Henry
Editorial: Clinical Investigation
-
Investigating the investigators: research malfeasance
Blair Henry
Editorial: Clinical Investigation
-
Investigating the investigators: research malfeasance
Blair Henry
Editorial: Clinical Investigation
-
Investigating the investigators: research malfeasance
Blair Henry
Editorial: Clinical Investigation
-
Investigating the investigators: research malfeasance
Blair Henry
Editorial: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Russell Katz
Russell Katz
Interview: Clinical Investigation
-
Are placebos inert or powerful? Vice versa
Beatrice A Golomb
Editorial: Clinical Investigation
-
Are placebos inert or powerful? Vice versa
Beatrice A Golomb
Editorial: Clinical Investigation
-
Are placebos inert or powerful? Vice versa
Beatrice A Golomb
Editorial: Clinical Investigation
-
Are placebos inert or powerful? Vice versa
Beatrice A Golomb
Editorial: Clinical Investigation
-
Are placebos inert or powerful? Vice versa
Beatrice A Golomb
Editorial: Clinical Investigation
-
Are placebos inert or powerful? Vice versa
Beatrice A Golomb
Editorial: Clinical Investigation
-
Distrust and minority trial participation: more than meets the eye
Raegan W Durant
Editorial: Clinical Investigation
-
Distrust and minority trial participation: more than meets the eye
Raegan W Durant
Editorial: Clinical Investigation
-
Distrust and minority trial participation: more than meets the eye
Raegan W Durant
Editorial: Clinical Investigation
-
Distrust and minority trial participation: more than meets the eye
Raegan W Durant
Editorial: Clinical Investigation
-
Distrust and minority trial participation: more than meets the eye
Raegan W Durant
Editorial: Clinical Investigation
-
Distrust and minority trial participation: more than meets the eye
Raegan W Durant
Editorial: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation
-
Sodium,glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Mark S Kipnes
Review Article: Clinical Investigation